Literature DB >> 24124085

Genetic sequence analysis of inherited bleeding diseases.

Flora Peyvandi1, Tom Kunicki, David Lillicrap.   

Abstract

The genes encoding the coagulation factor proteins were among the first human genes to be characterized over 25 years ago. Since then, significant progress has been made in the translational application of this information for the 2 commonest severe inherited bleeding disorders, hemophilia A and B. For these X-linked disorders, genetic characterization of the disease-causing mutations is now incorporated into the standard of care and genetic information is used for risk stratification of treatment complications. With electronic databases detailing >2100 unique mutations for hemophilia A and >1100 mutations for hemophilia B, these diseases are among the most extensively characterized inherited diseases in humans. Experience with the genetics of the rare bleeding disorders is, as expected, less well advanced. However, here again, electronic mutation databases have been developed and provide excellent guidance for the application of genetic analysis as a confirmatory approach to diagnosis. Most recently, progress has also been made in identifying the mutant loci in a variety of inherited platelet disorders, and these findings are beginning to be applied to the genetic diagnosis of these conditions. Investigation of patients with bleeding phenotypes without a diagnosis, using genome-wide strategies, may identify novel genes not previously recognized as playing a role in hemostasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24124085      PMCID: PMC4260973          DOI: 10.1182/blood-2013-05-505511

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  92 in total

Review 1.  Platelet genomics and proteomics in human health and disease.

Authors:  Iain C Macaulay; Philippa Carr; Arief Gusnanto; Willem H Ouwehand; Des Fitzgerald; Nicholas A Watkins
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Authors:  Paula D James; Colleen Notley; Carol Hegadorn; Jayne Leggo; Angie Tuttle; Shawn Tinlin; Christine Brown; Chandler Andrews; Andrea Labelle; Yvette Chirinian; Lee O'Brien; Maha Othman; Georges Rivard; Dilys Rapson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

3.  A case of non-resolving hemophilia B Leyden in a 42-year-old male (F9 promoter + 13 A>G).

Authors:  P D James; J Stakiw; J Leggo; I Walker; D Lillicrap
Journal:  J Thromb Haemost       Date:  2008-02-25       Impact factor: 5.824

Review 4.  Rare bleeding disorders.

Authors:  F Peyvandi; R J Kaufman; U Seligsohn; O Salomon; P H B Bolton-Maggs; M Spreafico; M Menegatti; R Palla; S Siboni; P M Mannucci
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

5.  The molecular analysis of haemophilia B: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network.

Authors:  M Mitchell; S Keeney; A Goodeve
Journal:  Haemophilia       Date:  2005-07       Impact factor: 4.287

6.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

Authors:  Anne Goodeve; Jeroen Eikenboom; Giancarlo Castaman; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Reinhard Schneppenheim; Ulrich Budde; Jorgen Ingerslev; David Habart; Zdena Vorlova; Lars Holmberg; Stefan Lethagen; John Pasi; Frank Hill; Mohammad Hashemi Soteh; Luciano Baronciani; Christer Hallden; Andrea Guilliatt; Will Lester; Ian Peake
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

7.  An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.

Authors:  Anthony Cumming; Pamela Grundy; Stephen Keeney; William Lester; Said Enayat; Andrea Guilliatt; Derrick Bowen; John Pasi; David Keeling; Frank Hill; Paula H B Bolton-Maggs; Charles Hay; Peter Collins
Journal:  Thromb Haemost       Date:  2006-11       Impact factor: 5.249

8.  Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII.

Authors:  Masayoshi Souri; Shiori Koseki-Kuno; Naoki Takeda; Mitsunori Yamakawa; Yasuchika Takeishi; Jay L Degen; Akitada Ichinose
Journal:  Thromb Haemost       Date:  2008-02       Impact factor: 5.249

Review 9.  Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes.

Authors:  Maha Othman
Journal:  Semin Thromb Hemost       Date:  2007-11       Impact factor: 4.180

10.  Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.

Authors:  Masayoshi Souri; Shiori Koseki-Kuno; Naoki Takeda; Jay L Degen; Akitada Ichinose
Journal:  Int J Hematol       Date:  2007-12-05       Impact factor: 2.490

View more
  9 in total

1.  From helix to hematology: introduction to a collection of reviews on the emerging role of next-generation sequencing in hematology.

Authors:  David M Bodine
Journal:  Blood       Date:  2013-09-09       Impact factor: 22.113

2.  TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.

Authors:  S Janapati; J Wurtzel; C Dangelmaier; B K Manne; D Bhavanasi; J C Kostyak; S Kim; M Holinstat; S P Kunapuli; L E Goldfinger
Journal:  J Thromb Haemost       Date:  2018-06-08       Impact factor: 5.824

3.  Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease.

Authors:  Alexander Tischer; Pranathi Madde; Laurie Moon-Tasson; Matthew Auton
Journal:  Biophys J       Date:  2014-09-02       Impact factor: 4.033

4.  Gene Therapy for Inherited Bleeding Disorders.

Authors:  Valder R Arruda; Jesse Weber; Benjamin J Samelson-Jones
Journal:  Semin Thromb Hemost       Date:  2021-02-26       Impact factor: 4.180

Review 5.  Treatment of rare factor deficiencies in 2016.

Authors:  Flora Peyvandi; Marzia Menegatti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  Combined variants in factor VIII and prostaglandin synthase-1 amplify hemorrhage severity across three generations of descendants.

Authors:  D Nance; R A Campbell; J W Rowley; J M Downie; L B Jorde; W H Kahr; S A Mereby; N D Tolley; G A Zimmerman; A S Weyrich; M T Rondina
Journal:  J Thromb Haemost       Date:  2016-10-20       Impact factor: 5.824

7.  Genetic Basis of Human Congenital Heart Disease.

Authors:  Shannon N Nees; Wendy K Chung
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-09-01       Impact factor: 9.708

8.  Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity.

Authors:  Irving Donadon; John H McVey; Isabella Garagiola; Alessio Branchini; Mimosa Mortarino; Flora Peyvandi; Francesco Bernardi; Mirko Pinotti
Journal:  Haematologica       Date:  2017-11-23       Impact factor: 9.941

9.  Identification of a novel mutation in the factor VIII gene causing severe haemophilia A.

Authors:  S K Nissen; A L Laursen; L H Poulsen; T H Mogensen
Journal:  BMC Hematol       Date:  2018-07-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.